GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
CNY 12.12
(2.02%)
CNY 12.12
(2.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.17 Billion CNY | 103.17% |
| 2022 | 578.39 Million CNY | 55.1% |
| 2021 | 372.92 Million CNY | 34.67% |
| 2020 | 276.91 Million CNY | 247.35% |
| 2019 | 79.72 Million CNY | 35.84% |
| 2018 | 58.68 Million CNY | -36.26% |
| 2017 | 92.07 Million CNY | 5.3% |
| 2016 | 87.43 Million CNY | 1.5% |
| 2015 | 86.13 Million CNY | -38.33% |
| 2014 | 139.66 Million CNY | 7.01% |
| 2013 | 130.52 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.2 Billion CNY | 2.03% |
| 2024 Q2 | 1.17 Billion CNY | 1.86% |
| 2024 Q1 | 1.15 Billion CNY | -1.67% |
| 2023 Q3 | 551.91 Million CNY | 3.49% |
| 2023 Q2 | 533.27 Million CNY | 1.0% |
| 2023 Q1 | 528.01 Million CNY | -8.71% |
| 2023 FY | 1.17 Billion CNY | 103.17% |
| 2023 Q4 | 1.17 Billion CNY | 112.92% |
| 2022 FY | 578.39 Million CNY | 55.1% |
| 2022 Q4 | 578.39 Million CNY | 24.19% |
| 2022 Q3 | 465.73 Million CNY | 6.74% |
| 2022 Q2 | 436.31 Million CNY | 12.73% |
| 2022 Q1 | 387.03 Million CNY | 3.78% |
| 2021 Q2 | 282.89 Million CNY | -5.83% |
| 2021 Q1 | 300.4 Million CNY | 8.48% |
| 2021 FY | 372.92 Million CNY | 34.67% |
| 2021 Q3 | 327.43 Million CNY | 15.74% |
| 2021 Q4 | 372.92 Million CNY | 13.89% |
| 2020 Q4 | 276.91 Million CNY | 74.16% |
| 2020 Q1 | 90.41 Million CNY | 13.42% |
| 2020 FY | 276.91 Million CNY | 247.35% |
| 2020 Q2 | 274.55 Million CNY | 203.65% |
| 2020 Q3 | 159 Million CNY | -42.09% |
| 2019 Q4 | 79.72 Million CNY | 0.0% |
| 2019 Q2 | 71.42 Million CNY | 0.0% |
| 2019 FY | 79.72 Million CNY | 35.84% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 Q2 | 86.13 Million CNY | 38.2% |
| 2018 Q4 | 58.68 Million CNY | 0.0% |
| 2018 FY | 58.68 Million CNY | -36.26% |
| 2018 Q1 | 62.32 Million CNY | -22.27% |
| 2017 FY | 92.07 Million CNY | 5.3% |
| 2017 Q4 | 80.17 Million CNY | 0.0% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q3 | 80.17 Million CNY | 0.0% |
| 2016 Q1 | 334.21 Million CNY | 287.99% |
| 2016 Q3 | 76.14 Million CNY | -77.22% |
| 2016 FY | 87.43 Million CNY | 1.5% |
| 2016 Q2 | 334.21 Million CNY | 0.0% |
| 2016 Q4 | 76.14 Million CNY | 0.0% |
| 2015 Q2 | 130.78 Million CNY | 0.0% |
| 2015 Q4 | 86.13 Million CNY | 7.63% |
| 2015 Q3 | 80.03 Million CNY | -38.81% |
| 2015 FY | 86.13 Million CNY | -38.33% |
| 2015 Q1 | 130.78 Million CNY | -6.36% |
| 2014 Q3 | 139.66 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q4 | 139.66 Million CNY | 0.0% |
| 2014 FY | 139.66 Million CNY | 7.01% |
| 2013 FY | 130.52 Million CNY | 0.0% |